Viemed Healthcare (VMD) vs. Its Rivals Financial Analysis

Viemed Healthcare (NASDAQ: VMD) is one of 27 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its rivals? We will compare Viemed Healthcare to related companies based on the strength of its dividends, profitability, risk, valuation, institutional ownership, earnings and analyst recommendations.

Risk and Volatility

Viemed Healthcare has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Viemed Healthcare’s rivals have a beta of 7.07, suggesting that their average stock price is 607% more volatile than the S&P 500.

Insider and Institutional Ownership

51.1% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 43.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 26.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Viemed Healthcare and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viemed Healthcare 21.32% 37.21% 25.66%
Viemed Healthcare Competitors -39.15% 16.05% -9.95%

Valuation & Earnings

This table compares Viemed Healthcare and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Viemed Healthcare $131.31 million $31.53 million 9.44
Viemed Healthcare Competitors $1.94 billion $96.17 million 42.06

Viemed Healthcare’s rivals have higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Viemed Healthcare and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare 0 1 2 0 2.67
Viemed Healthcare Competitors 92 389 536 15 2.46

Viemed Healthcare presently has a consensus price target of $12.50, indicating a potential upside of 70.07%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 6.89%. Given Viemed Healthcare’s stronger consensus rating and higher probable upside, equities analysts plainly believe Viemed Healthcare is more favorable than its rivals.

Summary

Viemed Healthcare beats its rivals on 7 of the 13 factors compared.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.